Fiche du document
22 février 2023
- doi: 10.53738/REVMED.2023.19.815.374
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2023.19.815.374
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/36815328
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_2C297F4168CD8
info:eu-repo/semantics/embargoedAccess , Restricted: cannot be viewed until 2024-08-22 , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Fatness Corpulence Overweight AdiposityCiter ce document
I. Ruiz et al., « Obésité infantile : nouveautés thérapeutiques ciblées [Obesity in infancy: new precision treatment] », Serveur académique Lausannois, ID : 10.53738/REVMED.2023.19.815.374
Métriques
Partage / Export
Résumé
Obesity is a chronical disease, which leads to multiple short- and long-term complications. 4% of Swiss children and adolescents are obese. A prompt diagnosis and multicomponent lifestyle intervention is mandatory to avoid persistence of the disease into adulthood. Growth and BMI charts are still the essential tools to diagnose and define the etiology of obesity. A precocious and severe obesity, accompanied by hyperphagia, will raise the suspicion of monogenic obesity. The precise molecular diagnosis enables in some patients the use of a specific treatment. Leptine in case of LEP gene defects, or setmelanotide when the affected gene is part of the MC4R signaling pathway (LEPR, POMC, PCSK1).